US Patent 8,071,623: Niraparib Compound Claims, Exclusivity, Orange Book Status, and Generic Entry Risk
US Patent 8,071,623 is the core composition-of-matter patent for niraparib, the active ingredient in GSK’s Zejula. Its strongest claims cover niraparib itself, its R-enantiomer, its S-enantiomer, the racemate, related fluorinated analogues, and pharmaceutical compositions containing the claimed compounds. The patent does not primarily protect a dose, indication, treatment regimen, manufacturing process, or formulation technology.
The patent’s central commercial claim is claim 8, which covers the S-enantiomer of niraparib:
2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
The patent is generally associated with an expiration date in January 2027, subject to any applicable patent-term adjustment or extension reflected in official records. Niraparib was approved by the FDA in 2017 and is not a biologic, so biosimilar substitution rules do not apply.
What drug does US Patent 8,071,623 protect?
US 8,071,623 protects niraparib, a small-molecule poly(ADP-ribose) polymerase, or PARP, inhibitor. Niraparib selectively inhibits PARP1 and PARP2 and is marketed in the United States as Zejula.
| Item |
Detail |
| Active ingredient |
Niraparib |
| Chemical identity |
2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
| Brand |
Zejula |
| Original sponsor |
Tesaro, Inc. |
| Current commercial owner |
GSK |
| Drug class |
PARP1/2 inhibitor |
| Dosage form |
Oral capsules and tablets |
| FDA approval |
March 27, 2017 |
| Patent at issue |
US 8,071,623 |
| Patent type |
Small-molecule composition of matter |
| Core commercial claim |
Claim 8 |
| Expected base patent expiration |
January 2027, subject to official term calculation |
The FDA approved niraparib for maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer responding to platinum-based chemotherapy. The approved population and indication have changed over time, including label restrictions associated with biomarker and clinical-benefit considerations. The patent itself is not limited to ovarian cancer or any other disease indication. [1]
What are the independent and dependent claims in US 8,071,623?
Claim 1 is the broadest compound claim supplied. It covers a formula I compound in which each of R1 and R2 is independently hydrogen or fluorine, together with pharmaceutically acceptable salts, stereoisomers, and tautomers.
Because the structural drawings for formulas I through IV are not reproduced in the supplied text, the exact ring connectivity of claims 1 through 4 cannot be independently reconstructed from the textual claim excerpt. The chemical scope of claims 5 through 8, however, is identifiable.
| Claim |
Scope |
Commercial significance |
| 1 |
Formula I compounds with R1 and R2 independently hydrogen or fluorine; salts, stereoisomers, tautomers |
Broad Markush compound claim |
| 2 |
Formula II compounds within claim 1 |
Subgenus claim |
| 3 |
Formula III compounds within claim 1 |
Subgenus claim |
| 4 |
Formula IV compounds within claim 1 |
Subgenus claim |
| 5 |
Ten expressly listed indazole-7-carboxamide compounds, including niraparib and fluorinated analogues |
Enumerated species claim |
| 6 |
The R- and S-enantiomers of 2-(4-piperidin-3-ylphenyl)-2H-indazole-7-carboxamide |
Enantiomer-specific claim |
| 7 |
Racemic 2-(4-piperidin-3-ylphenyl)-2H-indazole-7-carboxamide |
Racemate claim |
| 8 |
The S-enantiomer, niraparib |
Direct product claim for the marketed API |
| 9 |
Pharmaceutical composition containing a claim 1 compound and a pharmaceutically acceptable carrier |
Composition claim |
What compounds are covered by the patent?
The claim set covers four principal structural combinations under claim 1:
| R1 |
R2 |
General result |
| Hydrogen |
Hydrogen |
Unsubstituted indazole/phenyl analogue |
| Fluorine |
Hydrogen |
Mono-fluorinated analogue |
| Hydrogen |
Fluorine |
Alternative mono-fluorinated analogue, depending on formula position |
| Fluorine |
Fluorine |
Difluorinated analogue |
Claim 5 identifies ten species:
- Racemic 2-(4-piperidin-3-ylphenyl)-2H-indazole-7-carboxamide.
- The R-enantiomer.
- The S-enantiomer, niraparib.
- 5-Fluoro racemate.
- 5-Fluoro R-enantiomer.
- 5-Fluoro S-enantiomer.
- 5-Fluoro-3-fluoro phenyl analogue.
- The corresponding R-enantiomer.
- The corresponding S-enantiomer.
- Pharmaceutically acceptable salts, tautomers, and stereoisomers of the listed compounds.
Claim 8 is narrower than claim 1 but commercially more important because it directly identifies the active ingredient used in Zejula. A generic applicant seeking approval for niraparib would have to address claim 8 as well as any separately listed patents covering the approved product, uses, dosage forms, or regulatory information.
How strong is the patent estate for niraparib?
The strongest feature of US 8,071,623 is that it is a composition-of-matter patent directed to the active pharmaceutical ingredient. Composition claims generally present a higher generic-entry barrier than method-of-use or formulation claims because a product containing the claimed molecule directly practices the claim.
Strengths
- Claim 8 directly names the marketed S-enantiomer.
- Claim 7 covers the racemate.
- Claim 6 separately covers both stereoisomers.
- Claim 1 provides broader coverage for related analogues.
- Claim 9 reaches pharmaceutical compositions containing the claimed compounds.
- The patent is not dependent on a particular indication, dose, treatment duration, or administration schedule.
Limitations
- The patent does not expressly claim a method of treating cancer in the supplied claims.
- It does not claim a specific capsule or tablet formulation.
- It does not claim a particular release profile, excipient system, particle-size distribution, or manufacturing route.
- Claim 9 may be vulnerable to narrowing arguments if the carrier or composition language is interpreted narrowly, although a conventional generic oral product would ordinarily be designed to avoid unnecessary claim exposure where possible.
- The patent’s practical value declines sharply after expiration because a generic applicant would no longer need to avoid the compound claims.
When does niraparib lose patent exclusivity?
The base composition patent is generally reported to expire in January 2027. The relevant date is the expiration date recorded by the USPTO and FDA patent listings, rather than the patent’s issue date.
| Milestone |
Date or period |
| Earliest reported priority |
January 2007 |
| US patent filing family |
2008 |
| Patent issuance |
December 2011 |
| FDA approval of Zejula |
March 27, 2017 |
| Base patent expiration |
January 2027 |
| Earliest ordinary generic launch |
Potentially upon expiration, subject to litigation, settlement, exclusivity, and other listed patents |
The exact generic launch date can differ from the base patent expiration date. A first-filer may obtain 180-day shared or exclusive generic marketing rights. A settlement agreement may authorize an earlier launch. Other Orange Book-listed patents may delay approval or create additional litigation even after the composition patent expires.
The patent’s expiration should therefore be analyzed with the full Orange Book patent set, not US 8,071,623 in isolation.
What is the Orange Book status of niraparib?
Zejula is an FDA-approved small-molecule drug listed in the Orange Book. It is not listed in the Purple Book because the Purple Book covers biologics and biosimilars rather than conventional small-molecule drugs.
Orange Book analysis for niraparib should distinguish among:
- The active-ingredient patent.
- Method-of-use patents.
- Formulation or dosage-form patents.
- Patents associated with the approved labeling.
- Pediatric exclusivity, if granted.
- Any patent-term extension or adjustment.
- Any delisting, expiration, or litigation status recorded by FDA.
US 8,071,623 is the foundational product patent. Later patents may have narrower scope and may not prevent all generic products after the compound patent expires. A generic applicant can challenge some patents through a Paragraph IV certification while accepting others under Paragraph III or by using a label that omits the patented use.
What Paragraph IV challenges affect niraparib?
A generic applicant filing an ANDA for niraparib must certify against each applicable Orange Book patent. The main certification options are:
| Certification |
Meaning |
| Paragraph I |
No patent is listed |
| Paragraph II |
Listed patent has expired |
| Paragraph III |
Applicant will wait until patent expiration |
| Paragraph IV |
Patent is invalid, unenforceable, or not infringed |
A Paragraph IV notice against US 8,071,623 could assert that:
- The claims are invalid for lack of novelty or obviousness.
- The claims are not enabled across their full scope.
- The claims lack written description support.
- The proposed generic product does not fall within the claimed stereochemical or structural scope.
- The patent is unenforceable because of inequitable conduct or another litigation defense.
For a generic niraparib product, noninfringement of claim 8 would be difficult if the product contains the same S-enantiomer. The more realistic challenges would involve validity, patent-term calculations, or the relationship between the active ingredient and separately listed patents.
Under the Hatch-Waxman framework, a timely Paragraph IV notice can trigger a 30-month stay of FDA approval if the patent owner files suit within the statutory period. The stay does not automatically extend the patent term and can be shortened or terminated by court action. [2]
Which companies are challenging the Zejula patent estate?
Public generic activity around Zejula has involved the standard ANDA and patent-litigation process. The relevant parties may include generic manufacturers filing abbreviated applications and GSK or its subsidiaries defending listed patents.
The most important diligence point is that a company’s filing of an ANDA does not establish a commercial launch date. The outcome depends on:
- Whether the applicant made a Paragraph IV certification.
- Which patents were challenged.
- Whether GSK filed a timely infringement action.
- Whether the parties settled.
- Whether the court invalidated, narrowed, or upheld the patent.
- Whether FDA approval is blocked by another listed patent or exclusivity period.
Company-specific litigation conclusions should be drawn from PACER, district-court dockets, FDA Orange Book records, and settlement disclosures rather than from the patent claims alone. GSK’s securities filings identify Zejula patent litigation and generic competition as commercial risks but do not replace the docket-level record. [3]
Are formulation patents separate from US 8,071,623?
Yes. US 8,071,623 is primarily a compound patent. It does not, based on the supplied claims, establish detailed protection for:
- Capsule shell composition.
- Tablet formulation.
- Modified-release delivery.
- Specific excipient combinations.
- Coating technology.
- Particle engineering.
- Salt-selection technology.
- Dissolution specifications.
- Stability-enhancing packaging.
A generic applicant may therefore face two separate questions:
- Whether its API infringes the compound claims.
- Whether its finished dosage form infringes any later formulation or dosage-form patent.
Avoiding a formulation patent would not avoid infringement of claim 8 if the generic product still contains niraparib. Conversely, expiration or invalidation of the composition patent may leave residual formulation patents that create narrower litigation risk.
Does the patent cover methods of treatment?
The supplied claims do not contain a method-of-treatment claim. Claim 9 is a pharmaceutical composition claim, not a treatment method.
The patent therefore does not expressly require:
- Ovarian cancer treatment.
- BRCA mutation status.
- Homologous recombination deficiency.
- Platinum sensitivity.
- A maintenance-treatment setting.
- A particular dose or dosing schedule.
Separate method-of-use patents may protect treatment regimens or patient populations. Those patents can be addressed through a Paragraph IV challenge, a Paragraph III certification, or a section viii statement seeking approval with patented uses omitted from the label, depending on the patent and proposed product labeling.
Is there biosimilar risk for niraparib?
No. Niraparib is a synthetic small molecule, not a biologic. The relevant competitive pathway is an ANDA for a generic drug, not a biosimilar application under the Public Health Service Act.
The main competitive risks are:
- ANDA filings before or near composition-patent expiration.
- Paragraph IV litigation.
- At-risk launch after a court ruling.
- Authorized generic or settlement entry.
- Post-expiration price erosion.
- Competition among multiple generic suppliers.
How does niraparib compare with competing PARP inhibitors?
| Drug |
Active ingredient |
Company |
Primary patent-risk profile |
| Zejula |
Niraparib |
GSK |
Composition patent and later product/use patents |
| Lynparza |
Olaparib |
AstraZeneca/Merck |
Multiple compound, formulation, and method-of-use patents |
| Rubraca |
Rucaparib |
Clovis initially, later other commercial arrangements |
Compound and method-of-use patent estate |
| Talzenna |
Talazoparib |
Pfizer |
Strong compound and product-specific patent protection |
| Generic PARP inhibitors |
Various |
Multiple manufacturers |
Entry governed by patent expiry, certification, litigation, and settlement |
Niraparib’s principal early barrier is the direct compound claim in US 8,071,623. Its patent position should be compared with competing PARP inhibitors by examining the number of live patents, the earliest blocking expiration, the presence of formulation patents, and the scope of approved-use claims.
What revenue exposure does US 8,071,623 create?
Zejula revenue is exposed to a sharp change in competition when the core composition patent expires. The commercial impact depends on:
- Number of approved generic applicants.
- Timing of first generic entry.
- Whether a settlement permits an earlier launch.
- Whether additional patents remain enforceable.
- Net price discounts before and after generic entry.
- The share of sales from indications with unexpired method-of-use protection.
- Payer substitution and pharmacy-level generic substitution.
A composition-patent expiry typically creates more severe exposure than expiry of a narrow method patent because competing products can market the same active ingredient across non-patented indications, subject to applicable labeling rules.
What manufacturing and intellectual-property barriers remain?
The patent claims create a direct API barrier because a manufacturer producing niraparib would ordinarily make the claimed S-enantiomer. A generic company could challenge validity or infringement, but it cannot avoid the composition claim merely by changing:
- The salt form, if the salt remains within the claim.
- The tablet excipients.
- The capsule shell.
- The manufacturing site.
- The batch size.
- The commercial dosage strength.
The main technical and regulatory barriers after patent expiration are likely to involve API scale-up, stereochemical purity, impurity control, analytical equivalence, stability, bioequivalence, and supply reliability rather than a continuing monopoly over the underlying molecule.
Key Takeaways
- US 8,071,623 is the core niraparib composition patent.
- Claim 8 directly covers the S-enantiomer marketed as Zejula.
- Claim 7 covers the racemate, while claim 6 separately covers the R- and S-enantiomers.
- Claim 1 is a broader Markush claim covering hydrogen and fluorine substitution patterns.
- Claim 9 covers pharmaceutical compositions containing a claim 1 compound.
- The supplied claims do not directly cover a treatment method, dosage regimen, or specific formulation.
- The commonly reported base-patent expiration is January 2027.
- Niraparib faces generic, not biosimilar, competition.
- Generic entry requires analysis of every Orange Book-listed patent, Paragraph IV certification, litigation, settlement terms, and any remaining regulatory exclusivity.
- The commercial impact of expiration is potentially material because the patent covers the active ingredient itself.
FAQs About US Patent 8,071,623 and Niraparib
Does US 8,071,623 cover only the S-enantiomer of niraparib?
No. Claim 8 covers the S-enantiomer, but claims 1, 5, 6, and 7 cover broader classes, additional stereoisomers, the racemate, and fluorinated analogues.
Can a generic manufacturer avoid US 8,071,623 by using a different niraparib salt?
Not necessarily. The claims expressly include pharmaceutically acceptable salts. A salt change would not automatically avoid infringement.
Does US 8,071,623 protect Zejula’s capsule formulation?
The supplied claim 9 covers pharmaceutical compositions containing a claim 1 compound and a pharmaceutically acceptable carrier. It does not specify the detailed capsule formulation, excipients, coating, or release characteristics. Those features may be addressed by separate patents.
Is niraparib eligible for a biosimilar application?
No. Niraparib is a small-molecule drug. A competing manufacturer would generally use the ANDA pathway for a generic version.
What is the most important claim for a generic niraparib launch?
Claim 8 is the most commercially important because it expressly covers the S-enantiomer used as niraparib. A generic applicant must address that claim unless it can establish invalidity, unenforceability, noninfringement, or expiration.
References
- U.S. Food and Drug Administration. (2017). Zejula (niraparib) prescribing information.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
- GSK plc. (2024). Annual report 2023.
- United States Patent and Trademark Office. (2011). U.S. Patent No. 8,071,623: Substituted indazole compounds.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
